13 companies submit applications to the Hong Kong Stock Exchange Main Board on the same day; Maiwei Biotech passes the Hong Kong Stock Exchange Main Board listing hearing | HKEX early consultation

| April 8, 2026, Wednesday |

NO.1 13 companies file for listing on HKEX Main Board on the same day

According to HKEX news on April 2, Guangdong Chaohongji Industrial Co., Ltd. (SZ002345), New Hope Dairy Co., Ltd. (SZ002946), Puyuan Jingdian Technology Co., Ltd. (SH688337), Shenzhen Ruiming Technology Co., Ltd. (SZ002970), Zhejiang Maoyuanchang Eyewear Co., Ltd., Suzhou Helin Micro-Nano Technology Co., Ltd. (SH688661), Suzhou Tianhua New Energy Technology Co., Ltd. (SZ300390), Wuhan Bin Hui Biotechnology Co., Ltd. - B, Chando Global Holdings Limited, Anqing Computer Information Co., Ltd., Shanghai Huilun Pharmaceutical Co., Ltd., Shanghai Yijing Information Technology Co., Ltd., Casstime Holdings Ltd. (Kaisi Times Holdings Limited) have submitted listing applications to the HKEX Main Board.

Comment: The 13 companies collectively applying for listing on HKEX Main Board, with nearly half being A-share listed companies, highlights the hot IPO market in Hong Kong stocks.

NO.2 BaoGai New Material files again for the HKEX Growth Enterprise Market (GEM)

According to HKEX news on April 2, Shandong BaoGai New Material Technology Co., Ltd. (hereinafter BaoGai New Material) has once again submitted an application to the HKEX GEM, with Zhongtai International as its sole sponsor. The prospectus shows that BaoGai New Material was established in 2009 and has become a professional manufacturer in China’s composite material trench cover industry, mainly producing GFRP (glass fiber reinforced plastic) trench covers used to meet engineering and infrastructure needs.

Comment: As a leading player in the niche of composite material trench covers, BaoGai New Material’s demand from infrastructure and urban operation supports its core business. The renewed application reflects the company’s intention to raise funds for expansion.

NO.3 Maiwei Biotech passes HKEX Main Board listing hearing

According to HKEX news on April 2, Maiwei (Shanghai) Biotechnology Co., Ltd. (hereinafter Maiwei Biotech, SH688062) has passed the HKEX Main Board listing hearing, with CITIC Securities and Haitong International as joint sponsors. The prospectus indicates that Maiwei Biotech is a mainland pharmaceutical company mainly focused on independently developing drugs for tumors and age-related diseases, involving oncology, immunology, ophthalmology, orthopedics, and other fields. These diseases pose significant health risks globally and have unmet clinical needs.

Comment: With a competitive core pipeline and a rich product portfolio, Maiwei Biotech is expected to leverage Hong Kong stocks to broaden financing channels, accelerate clinical development, and commercial deployment.

NO.4 Hong Kong leads global IPO fundraising in Q1

On April 5, Hong Kong Financial Secretary Paul Chan Mo-po wrote in the “Secretary’s Notes” column on the Hong Kong Financial Services and the Treasury Bureau website. He mentioned that in the first quarter of this year, Hong Kong’s IPO fundraising exceeded HKD 103 billion, ranking first globally. More emerging industries, including artificial intelligence, semiconductors, and robotics, are listing in Hong Kong. Over 500 listing applications are pending, indicating that when the international environment is uncertain, more companies see Hong Kong as an important window for financing and “going global.”

Comment: Hong Kong’s IPO fundraising in the first quarter exceeded HKD 100 billion, topping the world, demonstrating strong global capital interest in Hong Kong stocks.

NO.5 Hong Kong stock market行情

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Operate at your own risk.

Daily Economic News